


**Provided for non-commercial research and educational use only.  
Not for reproduction or distribution or commercial use.**



This article was originally published by IWA Publishing. IWA Publishing recognizes the retention of the right by the author(s) to photocopy or make single electronic copies of the paper for their own personal use, including for their own classroom use, or the personal use of colleagues, provided the copies are not offered for sale and are not distributed in a systematic way outside of their employing institution.

Please note that you are not permitted to post the IWA Publishing PDF version of your paper on your own website or your institution's website or repository.

Please direct any queries regarding use or permissions to [wst@iwap.co.uk](mailto:wst@iwap.co.uk)

# Removal of pharmaceuticals using combination of UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> advanced oxidation process

Y. Lester, D. Avisar, I. Gozlan and H. Mamane

## ABSTRACT

Water and wastewater effluents contain a vast range of pharmaceutical chemicals. The present study aims to determine the potential of the advanced oxidation technology UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> and its sub-processes (i.e. UV, UV/H<sub>2</sub>O<sub>2</sub>, UV/O<sub>3</sub>, O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>) for the degradation of the antibiotics ciprofloxacin (CIP) and trimethoprim (TMP), and the antineoplastic drug cyclophosphamide (CPD) from water. Creating AOP conditions improved in most cases the degradation rate of the target compounds (compared with O<sub>3</sub> and UV alone). H<sub>2</sub>O<sub>2</sub> concentration was found to be an important parameter in the UV/H<sub>2</sub>O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> sub-processes, acting as <sup>•</sup>OH initiator as well as <sup>•</sup>OH scavenger. Out of the examined processes, O<sub>3</sub> had the highest degradation rate for TMP and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> showed highest degradation rate for CIP and CPD. The electrical energy consumption for both CIP and CPD, as calculated using the  $E_{EO}$  parameter, was in the following order: UV > UV/O<sub>3</sub> > UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> > O<sub>3</sub> > H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>. Whereas for TMP O<sub>3</sub> was shown to be the most electrical energy efficient. Twelve degradation byproducts were identified following direct UV photolysis of CIP.

**Key words** | advanced oxidation, byproducts, EEO, ozone, pharmaceuticals, photodegradation photolysis

Y. Lester  
H. Mamane (corresponding author)  
School of Mechanical Engineering,  
Faculty of Engineering,  
Tel Aviv University,  
Tel Aviv 69978,  
Israel  
E-mail: [hadasmg@post.tau.ac.il](mailto:hadasmg@post.tau.ac.il)

Y. Lester  
D. Avisar  
I. Gozlan  
The Hydro-chemistry Laboratory,  
Faculty of Geography and the Environment,  
Tel Aviv University,  
Tel Aviv 69978,  
Israel

## INTRODUCTION

Chemicals such as prescription drugs, contraceptive pills, household chemicals, detergents and cosmetics are excreted or discharged by humans as wastewater contaminants. Commonly used wastewater treatments do not sufficiently remove these contaminants, thus they may still remain in trace concentrations in the treated effluents. As a result, effluents containing micro-pollutants like pharmaceuticals enter rivers, groundwater and drinking water by direct discharge, irrigation or artificial recharge. Several studies conducted world-wide have confirmed the occurrence of pharmaceutical residues in wastewater treatment plants (WWTPs) (e.g. Hirsch *et al.* 1999), water streams (e.g. Kolpin *et al.* 2002), surface and ground-waters (e.g. Avisar *et al.* 2009).

The acute and chronic effects of pharmaceutical compounds on the ecosystem and on human health are not yet fully understood, yet the problem remains worrisome, due to many concerns as the possible development of antibiotic-resistance bacteria. Other concerns rise from the presence of toxic pharmaceuticals as antineoplastic drugs that are used in cancer chemotherapy. These drugs, typically originated from hospital wastewater, even though detected

in the environment at much lower concentrations in relation to other drugs, cannot be excluded as potential environmental contaminants due to their often carcinogenic and mutagenic properties (Kummerer 2001).

An attractive technology for the treatment of pharmaceuticals in water is the advanced oxidation process (AOP), where pollutants are chemically oxidized by a process that produces hydroxyl (<sup>•</sup>OH) free radicals. The hydroxyl radicals can be generated, for example, by the combined application of ozone/hydrogen peroxide (O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub>), ultraviolet radiation/ozone (UV/O<sub>3</sub>), UV/titanium dioxide (UV/TiO<sub>2</sub>) or UV/H<sub>2</sub>O<sub>2</sub>. Rosal *et al.* (2008) found AOP technologies (e.g. O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub>) to be efficient in the degradation of 33 organic compounds, treating effluent from two municipal WWTPs. Other researches have demonstrated the potential of UV/H<sub>2</sub>O<sub>2</sub> (Vogna *et al.* 2004; Lester *et al.* 2010) and UV/O<sub>3</sub> (Peyton & Glaze 1988) for the removal of different pharmaceuticals and other micro-pollutants from water and wastewater effluents. Among the O<sub>3</sub>- and UV-based AOPs, the combination of UV, O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub> (UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>), which employs several direct and indirect degradation

mechanisms, may present an attractive option for the degradation of a wide range of refractory pollutants. Several studies have already demonstrated the advantage of UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> over other AOPs in the degradation of phenol (Kusic *et al.* 2006) and 2-propanol (Wu *et al.* 2008) from water. However, information on this complex process and its potential in degrading pharmaceutical compounds is still lacking. Therefore, the objective of the current research is to determine the potential of the UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process for the degradation of commonly used pharmaceuticals, the antibiotics ciprofloxacin (CIP) and trimethoprim (TMP), and the antineoplastic drug cyclophosphamide (CPD). More specifically, this study aims to evaluate the efficiency of each of the sub-processes composing the UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process, namely: UV, O<sub>3</sub>, UV/H<sub>2</sub>O<sub>2</sub>, UV/O<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>, on the degradation of the selected pharmaceuticals.

## METHODS

### Chemicals

Pharmaceutical standards (>99% purity) were obtained from Sigma-Aldrich, ULC grade acetonitrile and water from Bio-Lab Ltd. (Jerusalem, Israel). All chemicals were used as obtained and pharmaceutical stock solutions were prepared by dissolving the compounds in deionized water (Direct-Q3 UV system, Millipore-France) at a concentration of 100 mg/L. H<sub>2</sub>O<sub>2</sub> (30% w/w, extra pure) was obtained from Merck (Germany). Unless otherwise mentioned, all experiments were conducted in 2.5 mM phosphate buffer saline (PBS) at pH 7.

### Experimental setup

#### UV Collimated Beam Apparatus (CBA)

A bench scale CBA was used to study the UV/H<sub>2</sub>O<sub>2</sub> process (described in detail elsewhere; Lester *et al.* 2010). In the CBA experiments, UV light is directed through a collimated tube to dose a sample solution. Experiments were carried out using a 0.45 kW medium-pressure (MP) polychromatic UV lamp emitting wavelengths at the range of 200–300 nm and above (Ace-Hanovia Lamp). The spectral incident irradiance obtained from a calibrated spectroradiometer (USB4000, Ocean Optics, FL, USA) was used to calculate the average irradiance and UV fluence (Bolton & Linden 2003).

#### UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> batch reactor

UV, O<sub>3</sub>, UV/O<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> experiments were performed in a temperature controlled (25 °C) 1 L glass cylindrical batch reactor. The center of the reactor is occupied with a quartz tube in which a 0.45 kW UV MP lamp is placed vertically (Ace-Hanovia). Average irradiance in the reactor was calculated to be  $6.7 \times 10^{-6}$  einstein/L s, using the NO<sub>3</sub><sup>-</sup> actinometer (Goldstein & Rabani 2008). Ozone is generated from pure oxygen (>99.9%) through an ozone generator (2–5 g/h, OZO-1VTT, Ozomax, Canada) and introduced into the aqueous solution using a diffuser located at the bottom of the reactor, while another tube carries the off-gases from the headspace of the reactor to the ozone destructor. The solution is continuously mixed with a magnetic stirrer. Dissolved ozone was quantified using the Indigo method (Bader & Hoigne 1981).

#### Determination of pharmaceutical rate constants with O<sub>3</sub>

Two different approaches were applied to determine the second-order rate constant values of the pharmaceuticals with molecular ozone ( $k_{O_3,C}$ , 1/M s). For CPD, with an expected low reactivity toward O<sub>3</sub>, experiments were conducted in the 1 L reactor in a full batch mode using O<sub>3</sub> in excess. Ozone was initially diffused into a solution containing *t*-butanol – an 'OH radical scavenger (10 mM) until the dissolved O<sub>3</sub> concentration reached 5 mg/L. Ozone diffusion was then stopped and CPD was injected (1 mg/L). Samples were withdrawn at appropriate time intervals, quenched with sodium thiosulfate, and analyzed with HPLC/MS. The rate constant of CPD with ozone was obtained by using the equation below:

$$-\frac{d[\text{CPD}]}{dt} = k_{O_3, \text{CPD}}[\text{O}_3] \times [\text{CPD}]$$

$$\Rightarrow \text{Ln} \frac{[\text{CPD}]_t}{[\text{CPD}]_0} = -k_{O_3, \text{CPD}} \int_0^t [\text{O}_3] dt \quad (1)$$

where, [CPD]<sub>0</sub> and [CPD]<sub>*t*</sub> are initial CPD concentrations (M) and its concentration after exposure time *t* (s),  $k_{O_3, \text{CPD}}$  is the second-order rate constant of CPD with molecular ozone (1/M s) and the time integral over O<sub>3</sub> concentration is the measured ozone exposure (M s).

For the highly ozone reactive CIP and TMP, competition kinetic (CK) procedure was used, where carbamazepine (CBZ) was selected as a reference compound due to its known rate constant with O<sub>3</sub> ( $k_{O_3, \text{CBZ}} =$

$3 \times 10^5$  1/M s; Huber *et al.* 2003). In the CK experiments, different understoichiometric doses of O<sub>3</sub> (at a range of 0.6–3.8 μM) were added separately to samples containing *t*-butanol (10 mM) and equal concentrations of the target and the reference compound (~4.5 μM each). The samples were continuously mixed during the experiments and the remaining concentrations of the target and reference compounds were analyzed by HPLC/MS. The second-order rate constants with ozone were then calculated as described below (Huber *et al.* 2003):

$$\text{Ln} \frac{[C]_H}{[C]_0} = \text{Ln} \frac{[\text{CBZ}]_H}{[\text{CBZ}]_0} \times \frac{k_{\text{O}_3, \text{C}}}{k_{\text{O}_3, \text{CBZ}}} \quad (2)$$

where,  $k_{\text{O}_3, \text{CBZ}}$  ( $3 \times 10^5$  1/M s, Huber *et al.* 2003) and  $k_{\text{O}_3, \text{C}}$  are the rate constants of O<sub>3</sub> with CBZ and the target compound, respectively. H represents the different applied O<sub>3</sub> doses.

### Determination of pharmaceutical rate constants with ·OH

The second-order rate constant of the pharmaceuticals with ·OH radical ( $k_{\text{OH}, \text{C}}$ , 1/M s) was calculated in the UV/H<sub>2</sub>O<sub>2</sub> CBA using the CK procedure (Elovitz *et al.* 2008), where *p*-chlorobenzoic acid (*p*CBA) was used as a reference compound due to its low direct photolysis rate. In brief, a mixture of the target pollutant and reference compound (at 1 mg/L each) was exposed to UV irradiation with and without H<sub>2</sub>O<sub>2</sub> (50 mg/L). Samples were withdrawn at two minute intervals for HPLC/MS analysis. In cases where the reaction with ·OH is the only degradation process (no direct photolysis), CK was used in its simplest form (Equation (2)). However, when direct photolysis played a significant role in the pollutant's UV/H<sub>2</sub>O<sub>2</sub> degradation, a correction was made to subtract the loss of the compound due to direct photolysis (Equation (3); Elovitz *et al.* 2008).

$$k_{\text{OH}, \text{C}} = \frac{(k_{\text{obs}, \text{C}} - [E_{\text{avg}}(\text{H}_2\text{O}_2)/E_{\text{avg}}(\text{w/o H}_2\text{O}_2)] \times k_{\text{d}, \text{C}})}{k_{\text{obs}, \text{pCBA}}} \times k_{\text{OH}, \text{pCBA}} \quad (3)$$

where,  $k_{\text{d}, \text{C}}$  is the pollutant's time-based pseudo-first-order direct photolysis rate constant (1/s),  $k_{\text{obs}, \text{C}}$  and  $k_{\text{obs}, \text{pCBA}}$  are the observed (total) time-based pseudo-first-order rate constants (1/s) for degradation of the target pollutant and *p*CBA respectively.  $k_{\text{OH}, \text{C}}$  and  $k_{\text{OH}, \text{pCBA}}$  are the second-order rate constants of the target pollutant and *p*CBA with ·OH ( $k_{\text{OH}, \text{pCBA}} = 5 \times 10^9$  1/M s; Buxton *et al.* 1988).  $E_{\text{avg}}(\text{H}_2\text{O}_2)/E_{\text{avg}}(\text{w/o H}_2\text{O}_2)$  is the ratio of the average

fluence rate with and without H<sub>2</sub>O<sub>2</sub>. This term is basically a weighting factor correcting for the pollutant's direct photolysis in the presence of H<sub>2</sub>O<sub>2</sub>.

## Pharmaceutical degradation experiments

### UV/H<sub>2</sub>O<sub>2</sub> experiments using the CBA

The tested pharmaceuticals were prepared in 100 mL at an initial concentration of 1 mg/L. Different concentrations of H<sub>2</sub>O<sub>2</sub> were added to generate the AOP process. Irradiation was performed with gentle stirring in a 7 × 5 cm crystallization dish open to the atmosphere. Samples of 0.5 mL were withdrawn at appropriate intervals for HPLC/MS analysis.

### UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> experiments using the 1 L batch reactor

All experiments were conducted in a semi-batch mode, where the ozone stream was continuously introduced into the aqueous solution. Initial pharmaceutical concentration was 1 mg/L. For the UV alone experiments, the UV lamp was preheated for 2 min before injecting the target compound. In O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> experiments, steady dissolved O<sub>3</sub> concentration was initially achieved prior to injection of the target compound and H<sub>2</sub>O<sub>2</sub>. For the UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> experiments, steady dissolved O<sub>3</sub> concentration was achieved prior to preheating UV lamp and injection of the target compound and H<sub>2</sub>O<sub>2</sub>. Samples (2 mL) were taken periodically after an initial mixing time of ~10 s, using a 20 cm syringe, quenched immediately with excess of sodium thiosulfate to decompose residual O<sub>3</sub> and analyzed chromatographically.

## Analytical methods

All pharmaceuticals were detected and quantified by HPLC-UV Agilent, model 1100 (ACE-RP C18 column 2.5 mm × 250 mm) and mass spectrometer (MS) detector (Finnigan LCQ). The HPLC consisted of a binary pump, microvacuum degasser, diode array detector and thermostatic column compartment. The column temperature was 32 °C, flow rate of 0.5 mL/min and injection volume of 100 μL. Positive electro-spray ionization MS mode was used where probe temperature was 220 °C. The flow from the HPLC was passed through a split connector with 60 μL/min of effluent introduced into the MS interface. Ions in the range 200–400 *m/z* were registered in the conventional scanning mode. For CIP and TMP, the HPLC mobile phase conditions were adapted from Lester *et al.* (2010)

with minor modifications. For CPD the mobile phase was ammonium formate 0.05 M (A) and methanol (B), at pH 5. The mobile phase eluent gradient started with 50% of eluent A followed by a 2.5-min linear gradient to 30% of eluent A, 3 min isocratic elution and a 2 min linear gradient back to 50% of eluent A, maintained for 4 min to equilibration time. For the detection of the CIP photo-products, irradiated samples were pre-concentrated by factor of 10 using lyophilization.

## RESULTS AND DISCUSSION

### Determination of pharmaceutical rate constants with O<sub>3</sub> and <sup>•</sup>OH

Table 1 summarizes the measured rate-constants for the three pharmaceuticals with O<sub>3</sub> and <sup>•</sup>OH and the used methods. Of the three compounds, TMP exhibits the highest reaction rate constants with both O<sub>3</sub> and <sup>•</sup>OH, while CPD reacts slowest.

The measured rate constants in the present study agree well with previously published results. The difference in rate constants between the three pharmaceuticals is due to basic structural differences. For example, the high rate constant of TMP with molecular O<sub>3</sub> is attributed to the presence of several amino moieties which react rapidly with O<sub>3</sub> (Huber *et al.* 2003).

### Pharmaceutical degradation by UV/H<sub>2</sub>O<sub>2</sub>

Time-based degradation of the studied pharmaceuticals by UV/H<sub>2</sub>O<sub>2</sub> using the CBA, with and without addition of 50 mg/L H<sub>2</sub>O<sub>2</sub>, is shown in Figure 1. The direct photolysis fluence-based rate constants were additionally calculated to be  $5.8 \times 10^{-3}$ ,  $3.4 \times 10^{-4}$  and  $2.3 \times 10^{-5}$  cm<sup>2</sup>/mJ for CIP, TMP and CPD respectively. Under direct UV light (no H<sub>2</sub>O<sub>2</sub>) CIP degradation rate was highest, while CPD only slightly degraded with UV. The differences in direct




Figure 1 | Degradation of CIP, TMP and CPD by UV/H<sub>2</sub>O<sub>2</sub> vs. time using the CBA, in PBS (2.5 mM, pH 7), with and without addition of 50 mg/L H<sub>2</sub>O<sub>2</sub>. Numbers in the legends (0 and 50) refer to H<sub>2</sub>O<sub>2</sub> concentration in mg/L.

photodegradation rates are due to the magnitude of the compound's molar absorption coefficients and its overlap with the emission spectra of the UV lamp, as well as differences in the compounds quantum yields.

As expected, addition of 50 mg/L H<sub>2</sub>O<sub>2</sub> to the photolysis process increased the degradation rate of all examined compounds, thus, the combined UV/H<sub>2</sub>O<sub>2</sub> process is more effective than UV alone, presumably due to <sup>•</sup>OH radical formation. Degradation of CPD in the UV/H<sub>2</sub>O<sub>2</sub> process was previously examined by Kim *et al.* (2009). Their study showed that addition of 6 mg/L H<sub>2</sub>O<sub>2</sub> to the photolysis process in pure water (using monochromatic UV lamp at 254 nm) increased the CPD degradation rate constant by factor of 12. For comparison, in the present study, addition of 50 mg/L H<sub>2</sub>O<sub>2</sub> to the photolysis process of CPD increased its degradation rate constant by a factor of ~90.

H<sub>2</sub>O<sub>2</sub> concentration is an important operating parameter in the UV/H<sub>2</sub>O<sub>2</sub> process. Figure 2 presents the UV/H<sub>2</sub>O<sub>2</sub> time-based degradation rate constants ( $k_{app}$ , 1/min) of the studied compounds as a function of H<sub>2</sub>O<sub>2</sub> initial concentration, in the range of 0–200 mg/L. The degradation rate of

Table 1 | Rate constants for the examined pharmaceuticals with <sup>•</sup>OH and O<sub>3</sub>


	<sup>•</sup> OH			O <sub>3</sub>		
	Method	Measured $k_{\text{OH,C}}$ (1/M s)	Literature $k_{\text{OH,C}}$ (1/M s)	Method	Measured $k_{\text{O}_3,\text{C}}$ (1/M s)	Literature $k_{\text{O}_3,\text{C}}$ (1/M s)
CIP	CK mod. <sup>a</sup>	$5.0 \times 10^9$	$4.1 \times 10^{9c}$	CK <sup>b</sup>	$2.2 \times 10^4$	$1.9 \times 10^{4c}$
TMP	CK <sup>b</sup>	$6.4 \times 10^9$	$6.9 \times 10^{9c}$	CK <sup>b</sup>	$4.5 \times 10^5$	$2.7 \times 10^{5c}$
CPD	CK <sup>b</sup>	$1.3 \times 10^9$	$2 \times 10^{9d}$	O <sub>3</sub> in excess	2.5	$3.3^d$

<sup>a</sup>Competition kinetic modified for direct photolysis (Equation (3)).

<sup>b</sup>Competition kinetic.

<sup>c</sup>Dodd *et al.* (2006).

<sup>d</sup>Garcia-Ac *et al.* (2010).



**Figure 2** | UV/H<sub>2</sub>O<sub>2</sub> time-based degradation rate constants ( $k_{app}$ ) of CIP, TMP and CPD, in PBS (2.5 mM, pH 7), at different initial H<sub>2</sub>O<sub>2</sub> concentrations.

CIP, CPD and TMP with UV was steadily increased with addition of H<sub>2</sub>O<sub>2</sub> at concentrations up to 150 mg/L. However, further increase in H<sub>2</sub>O<sub>2</sub> concentration above 150 mg/L, did not improve the degradation rate of the selected compounds. The tailing observed at H<sub>2</sub>O<sub>2</sub> concentrations higher than 150 mg/L is a well-documented phenomenon (e.g. Aleboye et al. 2004; Lester et al. 2010) and can be explained by the H<sub>2</sub>O<sub>2</sub> scavenging effect on  $\cdot$ OH and by the pharmaceuticals UV light screening due to H<sub>2</sub>O<sub>2</sub> light absorbance, both occur predominantly at high H<sub>2</sub>O<sub>2</sub> concentration. As a control experiment, the impact of H<sub>2</sub>O<sub>2</sub> alone was evaluated on the degradation of CIP, TMP and CPD (without UV light). No degradation of the compounds was observed when H<sub>2</sub>O<sub>2</sub> was used at concentration of 200 mg/L and contact times up to 48 h.

$\cdot$ OH radicals were previously indirectly quantified using the *p*CBA method (Lester et al. 2010). These results indicate a steady increase in  $\cdot$ OH radical concentration from  $2.9 \times 10^{-14}$  to  $4.7 \times 10^{-13}$  M when increasing H<sub>2</sub>O<sub>2</sub> initial concentration from 10 to 150 mg/L. A further increase in H<sub>2</sub>O<sub>2</sub> concentration to 200 mg/L had almost no effect on  $\cdot$ OH concentration (i.e.  $4.8 \times 10^{-13}$  M).

### Pharmaceutical degradation by UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>


In the UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> treatment,  $\cdot$ OH radicals are generated through several different processes where each can operate as an independent AOP (Glaze et al. 1987), namely: (a) O<sub>3</sub> reaction with OH<sup>-</sup>, (b) UV photolysis of H<sub>2</sub>O<sub>2</sub>, (c) the combined application of ozone and hydrogen peroxide and (d) UV photolysis of ozone, generating  $\cdot$ OH through a sequence of reactions, initiated by the formation of H<sub>2</sub>O<sub>2</sub>. In addition, direct degradation of the target pollutant may occur by UV photolysis and direct oxidation by ozone.

In order to better understand the UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> mechanism, each of the above processes was examined separately.

### Degradation by O<sub>3</sub>-based processes

Figure 3 illustrates the degradation of the pharmaceuticals in the ozone process, for different initial dissolved ozone concentrations (0.1–1 mg/L). Results for TMP were not plotted, as TMP completely degraded at the lowest ozone concentration of 0.1 mg/L, in less than 1 min. In all cases, a first order kinetic was observed, up to 30 min. For both CIP and CPD, degradation rate increased with an increase in initial ozone concentration. CPD showed the slowest degradation rate, at any ozone concentration, while TMP degraded the fastest. The observed degradation rates correlate well with the compound's calculated rate constants with O<sub>3</sub> and  $\cdot$ OH, as presented in Table 1. Previous studies have already demonstrated the low O<sub>3</sub> degradability of CPD (Kim et al. 2008) and the quick reaction of TMP and CIP with O<sub>3</sub> (Dodd et al. 2006).

Addition of H<sub>2</sub>O<sub>2</sub> to the ozone process creates AOP conditions and may enhance the degradation of the pharmaceuticals. Table 2 presents the pseudo-first-order time-based degradation rate constants of CIP and CPD, by the H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process ([O<sub>3</sub>]<sub>0</sub> = 0.5 mg/L), without H<sub>2</sub>O<sub>2</sub> and with the addition of H<sub>2</sub>O<sub>2</sub> at concentrations 0.17 and 0.35 mg/L. Results for TMP were not presented due to immediate O<sub>3</sub> degradation, as stated above. The degradation rate of CPD steadily increased with increase in H<sub>2</sub>O<sub>2</sub> concentration, while the degradation rate of CIP increased at low concentration of H<sub>2</sub>O<sub>2</sub> but decreased at the higher H<sub>2</sub>O<sub>2</sub> level. CIP reacts relatively fast with molecular O<sub>3</sub> ( $k_{O_3,CIP} = 2.2 \times 10^4$  1/M s), therefore, H<sub>2</sub>O<sub>2</sub> which competes with



**Figure 3** | Degradation of CIP and CPD with time at different initial dissolved O<sub>3</sub> concentrations in PBS (2.5 mM, pH 7). Numbers in the legends refer to initial O<sub>3</sub> concentration in mg/L.

**Table 2** | H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> time-based degradation rate constant ( $k_{app}$ , 1/min) of CIP and CPD at different H<sub>2</sub>O<sub>2</sub> initial concentrations. Initial O<sub>3</sub> dissolved concentration 0.5 mg/L


H <sub>2</sub> O <sub>2</sub> concentration (mg/L)	0	0.17	0.35
CIP	0.113	0.171	0.121
CPD	0.008	0.0164	0.0227

CIP over O<sub>3</sub>, may ultimately reduce its degradation rate. For CPD, direct reaction with O<sub>3</sub> is negligible, thus increasing H<sub>2</sub>O<sub>2</sub> concentration (within the tested range) will increase <sup>•</sup>OH formation, resulting in a higher degradation rate of CPD.

Kim *et al.* (2008) found that the addition of 2.3 mg/L H<sub>2</sub>O<sub>2</sub> to the O<sub>3</sub> process slightly improved the degradation rate of CPD, while De Witte *et al.* (2009) reported an improvement in degradation rate of CIP from water by O<sub>3</sub> with the addition of up to 1.7 mg/L H<sub>2</sub>O<sub>2</sub>. In contrast, Vasconcelos *et al.* (2009a) found that the H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process was slower than O<sub>3</sub> alone for the removal of CIP from wastewater effluent. Their results may be explained not only by the fast direct reaction of CIP with O<sub>3</sub>, but also by the scavenging effect of constituents in the wastewater effluent on <sup>•</sup>OH radicals.

### Degradation by UV-based processes

Time-based degradation of CIP and CPD by the UV, UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> processes (in the 1 L batch reactor) are presented in Figure 4. Initial concentration of dissolved O<sub>3</sub> (before pollutant's injection) was 0.5 mg/L (for UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>) and initial H<sub>2</sub>O<sub>2</sub> concentration was 2 mg/L (for UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>). At conditions studied, direct UV showed the slowest degradation rate for both compounds. For CPD, degradation rate decreased as follow:

**Figure 4** | Degradation of CPD and CIP with time by the UV, UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> processes in PBS (2.5 mM, pH 7) ([O<sub>3</sub>]<sub>0</sub> = 0.5 mg/L; [H<sub>2</sub>O<sub>2</sub>]<sub>0</sub> = 2 mg/L).

UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> > UV/O<sub>3</sub> > UV. While for CIP the UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> processes showed almost similar degradation rate, thus the addition of H<sub>2</sub>O<sub>2</sub> to the UV/O<sub>3</sub> process have practically no additional value on the degradation rate of CIP.

Wang *et al.* (2005) studied the impact of different AOPs on the degradation of three chlorophenols found in a Kraft-pulp bleach plant effluent. Their study showed that degradation efficacy of each AOP was compound dependent. For example the addition of H<sub>2</sub>O<sub>2</sub> to an UV/O<sub>3</sub> system improved the degradation rate of 2, 3, 4, 5-tetrachlorophenol and had no effect on the degradation of 4, 5-dichloroguaiacol. Kusic *et al.* (2006) found that phenol decay was similar in the UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> processes; however, UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> achieved higher mineralization (i.e. TOC removal). Thus, the UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process may have an advantage over other AOPs in the degradation of specific (i.e. refractory) target compounds, as well as in their mineralization. Complete mineralization of the target pollutant is advantageous due to possible unwanted formation of active intermediate byproducts resulting from the degradation of the parent compound.

### Electrical energy efficiency

The electrical-energy per order parameter ( $E_{EO}$ ) was determined, as the studied degradation processes are electrical energy related processes. The  $E_{EO}$  parameter corresponds to the amount of electrical energy (kWh) required to reduce one order of magnitude (90% removal of contaminant) in a treated volume of contaminated water (Bolton *et al.* 2001).

$$E_{EO} = \frac{P}{26.1 \times V \times k_{app}} \quad (4)$$

where,  $P$  is the rated power of the system (kW),  $V$  is the total volume of water treated (m<sup>3</sup>) and  $k_{app}$  is the time-based degradation rate constant of the examined compound (1/min).

The rated power was calculated as the sum of the UV lamp power (0.45 kW), the O<sub>3</sub> production power and the energy cost of H<sub>2</sub>O<sub>2</sub>. Where, the O<sub>3</sub> production power

**Table 3** |  $E_{EO}$  values (kWh/m<sup>3</sup>/order) of CIP and CPD at different processes

	UV	UV/O <sub>3</sub>	UV/H <sub>2</sub> O <sub>2</sub> /O <sub>3</sub>	O <sub>3</sub>	H <sub>2</sub> O <sub>2</sub> /O <sub>3</sub>
CIP	16.3	5.2	5.1	3.2	2.2
CPD	70.7	59.1	37.8	19.7	7.2

**Table 4** | HPLC/MS analysis of CIP direct UV degradation byproducts

N° (m/z)	Rt <sup>a</sup>	Proposed product structures	N° (m/z)	Rt <sup>a</sup>	Proposed product structures
CIP (332.1)	4.9				
1 (316.1)	2.9		7 (288.1)	7.0	
2 (316.1)	6.1		8 (334.1)	3.4	
3 (330.1)	2.8		9 (334.1)	6.8	
4 (330.1)	7		10 (306.1)	4.0	
5 (344.1)	5.5		11 (263.1)	7.5	
6 (346.1)	4.4		12 (288.1)	3.2	

<sup>a</sup>MS retention time (min).

was based on the product of the measured current and voltage of the ozone generator and the energy cost of H<sub>2</sub>O<sub>2</sub> was calculated as the ratio between the local costs of H<sub>2</sub>O<sub>2</sub> (US\$/mg) and electricity (US\$/kWh). It should be noted however that at the examined H<sub>2</sub>O<sub>2</sub> range it had only minor contribution to the  $E_{EO}$  value.  $E_{EO}$  results for CIP and CPD in the 1 L batch reactor, for each of the examined process, are presented in Table 3. For the O<sub>3</sub>-based process  $E_{EO}$  was calculated for initial O<sub>3</sub> concentration of 0.5 mg/L. For the H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> process  $E_{EO}$  was calculated for initial H<sub>2</sub>O<sub>2</sub> concentration of 0.17 and 0.35 mg/L for CIP and CPD respectively.

From Table 3 it can be concluded that for the studied compounds and operating parameters, the O<sub>3</sub>-based processes (i.e. O<sub>3</sub> and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>) consume less electrical energy than the processes where UV light was used. The electrical energy consumption for CPD was in the following order: UV > UV/O<sub>3</sub> > UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> > O<sub>3</sub> > H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>, while for CIP  $E_{EO}$  was similar for UV/O<sub>3</sub> and UV/H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>, thus, the most energy-efficient process was the combination H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub>. Earlier studies have confirmed the advantage of O<sub>3</sub>-based processes over UV-based processes in terms of energy efficiency (e.g. Muller & Jekel 2001).

### Photo-degradation intermediates analysis

The formation of intermediate byproducts, following the degradation of an organic pollutant by UV- or O<sub>3</sub>-based processes, is one of the most important issues in the field of pharmaceutical removal. Active degradation intermediates may occasionally be formed, in particular if the active part of the molecule remains unmodified. The importance of this topic is demonstrated in Table 4, where 12 byproducts, identified during direct UV photolysis of CIP, are presented. The moieties which are involved in the CIP photo-degradation are the piperazine residue, the carboxylic group and the fluorine atom. The quinolone skeleton however remains unchanged. The piperazine ring is either subjected to breakdown (intermediates 1–2, 4–5 and 8–12) or is epoxidized at positions 2, 3 (of the piperazine) (intermediate 6). Decarboxylation occurs at position 3 of the quinolone skeleton (intermediate 7). The fluorine at position 6 is either substituted by hydroxyl group (intermediate 3) or by hydrogen atom (intermediates 1, 2, 4, 5 and 12). Various researchers have already identified the formation different byproducts as a result of CIP photo-degradation (e.g. Vasconcelos *et al.* 2009b). In light of the fact that the characteristic quinolone

is believed to be responsible for the CIP antimicrobial activity (Dodd *et al.* 2006), intermediates which merely involve modification of the piperazine residue may still potentially exhibit antibacterial potencies.

### CONCLUSIONS

AOPs which combine UV photolysis, hydrogen peroxide and ozone may present an attractive treatment for the degradation of a wide range of pharmaceuticals in water. Out of the examined processes, O<sub>3</sub> had the highest degradation rate for TMP and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> showed highest degradation rate for CIP and CPD. H<sub>2</sub>O<sub>2</sub> concentration was found to be an important parameter in the UV/H<sub>2</sub>O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> sub-processes, acting as an 'OH initiator at low concentrations and as an 'OH radical scavenger at higher concentrations. The electrical energy consumption, as calculated using the  $E_{EO}$  parameter, showed that O<sub>3</sub>-based processes were more efficient than UV-based processes, where O<sub>3</sub> was the most efficient process for the degradation of TMP, and H<sub>2</sub>O<sub>2</sub>/O<sub>3</sub> was the most efficient process for the degradation of CIP and CPD. Twelve degradation byproducts were identified following direct UV photolysis of CIP. Future research will investigate the formation of degradation byproducts for CIP, CPD and TMP under the different AOP conditions and evaluate their potential toxicity.

### ACKNOWLEDGEMENT

We greatly acknowledge financial support of the Israeli Water Authority.

### REFERENCES

- Aleboye, A., Aleboye, H. & Moussa, Y. 2004 'Critical' effect of hydrogen peroxide in and p-xylene (BTEX) in aqueous solutions using UV/H<sub>2</sub>O<sub>2</sub> system. *J. Chem. Technol. Biot.* **79**, 468–474.
- Avisar, D., Lester, Y. & Ronen, D. 2009 Sulfamethoxazole contamination of a deep phreatic aquifer. *Sci. Total Environ.* **407**, 4278–4282.
- Bader, H. & Hoigne, J. 1981 Determination of ozone in water by the indigo method. *Water Res.* **15**, 449–456.
- Bolton, J. R., Bircher, K. G., Tumas, W. & Tolman, C. A. 2001 Figures-of-Merit for the technical development and application of advance oxidation technologies for both electric and solar-driven systems. *Pure Appl. Chem.* **73**, 627–637.

- Bolton, J. R. & Linden, K. G. 2003 Standardization of methods for fluence (UV dose) determination in bench-scale UV experiments. *J. Environ. Eng.-ASCE* **129**, 209–215.
- Buxton, B. V., Greenstock, C. L., Helman, W. P. & Ross, A. B. 1988 Critical review of rate constants for reactions of hydrated electrons, hydrogen atoms, and hydroxyl radicals in aqueous solution. *J. Phys. Chem. Ref. Data* **17**, 513–586.
- De Witte, B., Dewulf, J., Demeestere, K. & Van Langenhove, H. 2009 Ozonation and advanced oxidation by the peroxide process of ciprofloxacin in water. *J. Hazard. Mater.* **161**, 701–708.
- Dodd, M. C., Buffle, M. O. & Von-gunten, U. 2006 Oxidation of antibacterial molecules by aqueous ozone: moiety-specific reaction kinetics and application to ozone-based wastewater treatment. *Environ. Sci. Technol.* **40**, 1969–1977.
- Elovitz, M. S., Shemer, H., Peller, J. R., Vinodgopal, K., Sivaganesan, M. & Linden, K. G. 2008 Hydroxyl radical rate constants: comparing UV/H<sub>2</sub>O<sub>2</sub> and pulse radiolysis for environmental pollutants. *J. Water Supply Res.* **57**, 391–401.
- Garcia-Ac, A., Broseus, R., Vincent, S., Barbeau, B., Prevost, M. & Sauve, S. 2010 Oxidation kinetics of cyclophosphamide and methotrexate by ozone in drinking water. *Chemosphere* **79**, 1056–1063.
- Goldstein, S. & Rabani, J. 2008 Polychromatic UV photon irradiance measurements using chemical actinometers based on NO<sub>3</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> excitation: Applications for industrial photoreactors. *Environ. Sci. Technol.* **42**, 3248–3253.
- Glaze, W. H., Kang, J. W. & Chapin, D. H. 1987 The chemistry of water treatment processes involving ozone, hydrogen peroxide and ultraviolet light. *Ozone Sci. Eng.* **9**, 335–352.
- Hirsch, R., Ternes, T., Haberer, K. & Kratz, K. L. 1999 Occurrence of antibiotics in the aquatic environment. *Sci. Total Environ.* **225**, 109–118.
- Huber, M. M., Canonica, S., Park, G. Y. & Von Gunten, U. 2003 Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. *Environ. Sci. Technol.* **37**, 1016–1024.
- Kim, I. H., Tanaka, H., Iwasaki, T., Takubo, T., Morioka, T. & Kato, Y. 2008 Classification of the degradability of 30 pharmaceuticals in water with ozone, UV and H<sub>2</sub>O<sub>2</sub>. *Water Sci. Technol.* **57**, 195–200.
- Kim, I., Yamashita, N. & Tanaka, H. 2009 Photodegradation of pharmaceuticals and personal care products during UV and UV/H<sub>2</sub>O<sub>2</sub> treatments. *Chemosphere* **77**, 518–525.
- Kolpin, D. W., Furlong, E. T., Meyer, M. T., Thurman, E. M., Zaugg, S. D., Barber, L. B. & Buxton, H. T. 2002 Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: a national reconnaissance. *Environ. Sci. Technol.* **36**, 1202–1211.
- Kummerer, K. 2001 Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources – a review. *Chemosphere* **45**, 957–969.
- Kusic, H., Koprivanac, N. & Bozic, A. L. 2006 Minimization of organic pollutant content in aqueous solution by means of AOPs: UV- and ozone-based technologies. *Chem. Eng. J.* **123**, 127–137.
- Lester, Y., Avisar, D. & Mamane, H. 2010 Photodegradation of the antibiotic sulfamethoxazole in water with UV/H<sub>2</sub>O<sub>2</sub> advanced oxidation process. *Environ. Technol.* **31**, 175–183.
- Muller, J. P. & Jekel, M. 2001 Comparison of advanced oxidation processes in flow-through pilot plants (Part I). *Water Sci. Technol.* **44**, 303–309.
- Peyton, G. R. & Glaze, W. H. 1988 Destruction of pollutants in water with ozone in combination with ultraviolet radiation. 3. Photolysis of aqueous ozone. *Environ. Sci. Technol.* **22**, 761–767.
- Rosal, R., Rodriguez, A., Perdigon-Melona, J. A., Mezcuua, M., Hernando, M. D., Letona, P., Garcia-Calvo, E., Aguera, A. & Fernandez-Alba, A. R. 2008 Removal of pharmaceuticals and kinetics of mineralization by O<sub>3</sub>/H<sub>2</sub>O<sub>2</sub> in a biotreated municipal wastewater. *Water Res.* **42**, 3719–3728.
- Vasconcelos, T. G., Kummerer, K., Henriques, D. M. & Martins, A. F. 2009a Ciprofloxacin in hospital effluent: degradation by ozone and photoprocesses. *J. Hazard. Mater.* **169**, 1154–1158.
- Vasconcelos, T. G., Henriques, D. M., König, A., Martins, A. F. & Kummerer, K. 2009b Photo-degradation of the antimicrobial ciprofloxacin at high pH: identification and biodegradability assessment of the primary by-products. *Chemosphere* **76**, 487–493.
- Vogna, D., Marotta, R., Napolitano, A., Andreozzi, R. & d'Ischi, M. 2004 Advanced oxidation of the pharmaceutical drug diclofenac with UV/H<sub>2</sub>O<sub>2</sub> and ozone. *Water Res.* **38**, 414–422.
- Wang, R., Chen, C. L. & Gratzl, J. S. 2005 Dechlorination of chlorophenols found in pulp bleach plant E-1 effluents by advanced oxidation processes. *Bioresour. Technol.* **96**, 897–906.
- Wu, J. J., Yang, J. S., Muruganandham, M. & Wu, C. C. 2008 The oxidation study of 2-propanol using ozone-based advanced oxidation processes. *Sep. Purif. Technol.* **62**, 39–46.